An Irish commentator warns that Ireland must reinforce its regulatory safeguards against unapproved peptide products, as US Health Secretary Robert F. Kennedy Jr. pushes to expand access. The article details how Kennedy installed industry-linked members on an FDA committee that voted to recommend…
Ireland should welcome legitimate peptide research but must demand the same rigorous standards applied to any medicine: manufacturing data, toxicology, controlled trials, and honest reporting. This is the central argument made by Terence Cosgrave in a commentary published on 30th July 2026. Cosgrave warns that without proactive measures, Ireland could see a flood of unapproved 'wellness peptides' entering the market, echoing developments in the United States where regulatory barriers are being lowered under Health Secretary Robert F. Kennedy Jr.
The commentary draws a sharp distinction between approved peptide medicines such as insulin and GLP-1-based treatments for diabetes and obesity, and the unregulated 'wellness peptides' popular in America. These include compounds like BPC-157, TB-500, KPV, MOTS-c, Semax, and epitalon. They are promoted for healing, longevity, muscle growth, inflammation reduction, weight loss, and neurological complaints. However, Cosgrave notes, many of these substances lack adequate human trials and have not been proven safe or effective for their marketed uses.
Kennedy has publicly declared himself a 'big fan' of peptides and has used them himself with reported good effect, though Cosgrave points out that Kennedy also used heroin for years and approved of that substance. The Health Secretary has promised to reverse restrictions imposed by the FDA in 2023, when the agency identified safety concerns and a lack of clinical evidence regarding these peptides. Kennedy’s actions have been more than just rhetorical. He installed eight new members on the FDA’s Pharmacy Compounding Advisory Committee before its July 2026 meeting. According to reporting by Merrill Goozner, six of those eight new members work in wellness, longevity, or regenerative medicine businesses that prescribe peptides. The usual FDA conflict-of-interest vetting was bypassed for these appointments.
The Associated Press similarly found that more than half a dozen additions had professional or commercial connections to the peptide industry. With this reconstituted committee in place, the panel voted, mostly by narrow margins, to recommend that six peptides be placed on the list of substances that pharmacies may use in compounded medicines. This was, Cosgrave observes, the very purpose for which these individuals were added to the committee.
The disturbing feature, according to Cosgrave, is that the committee moved against the conclusions of the FDA’s own scientists. Staff reviewers found little reliable evidence that the seven substances under consideration were safe or effective for the proposed uses. The FDA identified only a few short, small, and exploratory studies for BPC-157, and no human studies using TB-500. For several products, even the identity and pharmaceutical form of the substance were uncertain. Cosgrave warns that a medicine whose name does not reliably tell you what is in the vial is less a therapeutic product than a biochemical raffle.
Goozner, whom Cosgrave cites, identifies what he calls the real scandal: Kennedy is not merely encouraging patients to take a chance; he is helping to alter the machinery that decides what counts as evidence. Advisers with commercial stakes can recommend wider access; pharmacies and telehealth companies can sell the products; and thousands of customers become participants in an uncontrolled experiment. No protocol unites them, no comparator group exists, adverse events may never be systematically captured, and failure can easily be blamed on the dose, the patient, or an insufficiently adventurous stack. The seller collects revenue while society collects anecdotes. Cosgrave illustrates this with a cynical pair of outcomes: “It worked for my cousin / My cousin is dead ”
Injecting unapproved peptides adds risks beyond any question of whether the peptide performs its advertised function. The customer must trust that the vial contains the declared molecule at the declared strength, without contamination or degradation. There are unknown toxicities, immune reactions, drug interactions, and longer-term effects. Compounding can be legitimate and valuable when an authorised product cannot meet an individual patient’s need. But Cosgrave argues it becomes hazardous when used as a side entrance through which an undeveloped drug is ushered around the clinical-trial system.
Kennedy’s peptide enthusiasm reverses the proper order of medicine, Cosgrave contends. The orthodox sequence is evidence first, access afterwards. Kennedy’s approach is access first, followed by the hope that evidence will wander in later wearing a clean shirt. Supporters argue that people already buy peptides from grey-market suppliers, so legal compounding would provide safer products. Cosgrave acknowledges some practical force in that argument but insists it does not establish efficacy, and commercial availability creates demand as well as satisfying it. He concludes that the cure for an unregulated market is not a larger market decorated with prescriptions.
He recommends that the HPRA, the Medical Council, and the Pharmaceutical Society of Ireland should issue joint guidance naming the fashionable compounds and distinguishing them from approved peptide medicines. Prescribers should be required to record the clinical rationale, evidence, source, consent, monitoring, and adverse-event plan whenever an unauthorised peptide is proposed. Routine use for anti-ageing, bodybuilding, vague recovery, or optimisation should occur only in a properly approved clinical trial.
Enforcement must follow the trade onto social media, Cosgrave argues. Irish law applies to online medicines advertising, and public promotion must be accurate, non-misleading, and consistent with authorised product information. The HPRA and Revenue should monitor influencers, telehealth vendors, and imported vials; use test purchases where lawful; and rapidly notify platforms and payment providers about illegal sellers. Ireland has already seen counterfeit injectable products in which the contents did not match the label. This is not an imaginary danger.
Finally, Cosgrave states that doctors and patients need one clear message: ‘peptide’ describes a molecule, not a standard of proof. Good peptide medicines have survived trials and regulatory scrutiny. The American wellness compounds largely have not. Ireland should welcome proper research but require its familiar luggage: manufacturing data, toxicology, controlled trials, and honest reporting.
The commentary closes by acknowledging America’s cultural gifts: jazz, cardiology, and several delicious sandwiches. But America has also produced medical enthusiasms wearing a white coat borrowed from science while being naked underneath. Kennedy is now helping this particular enthusiasm through the regulatory door. Cosgrave concludes that Ireland should bolt that door, not against peptide science, but against the doctrine that popularity, political favour, and a narrow ‘stacked’ committee vote can do the work of evidence.
Peptides referenced: BPC-157, TB-500, MOTS-c, Epithalon, Semax, GLP-1.
Vendors referenced: Wellness Peptides.
Related reading: How Are People Already Using Retatrutide Before Its Official Release?, GLP-1s Are Cutting My AUD Patients’ Hospitalizations. Trial Designers Need to Know Why., 'Super weight loss' drug retatrutide could be stronger than Wegovy and Zepbound, doctor says - FOX 17 West Michigan News, Danish weight-loss firm starts phase 2 study for obesity and diabetes.